Cocrystal Pharma, Inc. (COCP) — SEC Financial Statements & Analysis

Cocrystal Pharma, Inc. (COCP) is a pharmaceutical preparations company, incorporated in DE. Cocrystal Pharma, Inc. trades on Nasdaq as: COCP. Cocrystal Pharma, Inc. (COCP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Cocrystal Pharma, Inc. carries a market cap of $14.48M, a P/E ratio of -1.46x, a P/B ratio of 13.87x, a P/S ratio of 43.87x, an enterprise value of $12.31M, and an EV/EBITDA multiple of -1.22x. On profitability, it posts an operating margin of -3063.64%, a net margin of -3011.52%, a Return on Equity (ROE) of -311.68%, a Return on Assets (ROA) of -151.10%, and a Return on Invested Capital (ROIC) of -2852.75%. Per share, it reports EPS of $-0.72, diluted EPS of $-0.72, free cash flow per share of $-0.58, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -20.88% year-over-year and EPS growth of -41.62% year-over-year. On the balance sheet, it maintains a current ratio of 1.24x, a quick ratio of 1.14x, working capital of $620.00K, a debt-to-equity ratio of 3.45x, a debt ratio of 0.78, an interest coverage ratio of -100.10x, free cash flow of $-7.97M (TTM), and net debt of $-2.17M. Figures sourced from SEC EDGAR.

Market Cap

$14.48M

P/E TTM

-1.46x

EPS TTM

$-0.72

P/B TTM

13.87x

ROE TTM

-311.68%

ROA TTM

-151.10%

Debt To Equity

3.45x

Free Cash Flow TTM

$-7.97M

Data as of 2026-06-30 · Source: SEC EDGAR